Todos Medical’s Letter of Intent with Provista Diagnostics set to license sepsis diagnostic testing

News Direct

Mar 31, 2023

–News Direct–

Todos Medical president and CEO Gerald Commissiong joins Proactive's Natalie Stoberman to discuss news of the company entering a Letter of Intent with Provista Diagnostics to license PCR-based sepsis diagnostic test AcuSept LDT rights From Acumen Diagnostics.

Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/todos-medicals-letter-of-intent-with-provista-diagnostics-set-to-license-sepsis-diagnostic-testing-214995662

YOU MAY ALSO LIKE

Carlie Hanson pays tribute with her heartfelt…

--News Direct--Todos Medical president and CEO Gerald Commissiong joins Proactive's Natalie Stoberman to discuss news of the company entering a Letter of Intent with Provista…

read more

Florida Governor Signs Bill Increasing Motor Vehicle…

--News Direct--Todos Medical president and CEO Gerald Commissiong joins Proactive's Natalie Stoberman to discuss news of the company entering a Letter of Intent with Provista…

read more

HBO announces listing and issue tokens

--News Direct--Todos Medical president and CEO Gerald Commissiong joins Proactive's Natalie Stoberman to discuss news of the company entering a Letter of Intent with Provista…

read more